CoChat
Sign Up
Cited by 1,183Atherosclerosis and Cardiovascular DiseasesInflammasome and immune disordersCholesterol and Lipid Metabolism

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

Open access
Kong, Peng, Cui, Zi-Yang, Huang, Xiao-Fu, Zhang, Dan-Dan, Guo, Rui-Juan, Han, Mei·2022·Signal Transduction and Targeted Therapy
DOI 10.1038/s41392-022-00955-7PMC PMC9033871
Open this paper in CoChat — free accountOpen PDF

Abstract

Atherosclerosis is a chronic inflammatory vascular disease driven by traditional and nontraditional risk factors. Genome-wide association combined with clonal lineage tracing and clinical trials have demonstrated that innate and adaptive immune responses can promote or quell atherosclerosis. Several signaling pathways, that are associated with the inflammatory response, have been implicated within atherosclerosis such as NLRP3 inflammasome, toll-like receptors, proprotein convertase subtilisin/kexin type 9, Notch and Wnt signaling pathways, which are of importance for atherosclerosis development and regression. Targeting inflammatory pathways, especially the NLRP3 inflammasome pathway and its regulated inflammatory cytokine interleukin-1β, could represent an attractive new route for the treatment of atherosclerotic diseases. Herein, we summarize the knowledge on cellular participants and key inflammatory signaling pathways in atherosclerosis, and discuss the preclinical studies targeting these key pathways for atherosclerosis, the clinical trials that are going to target some of these processes, and the effects of quelling inflammation and atherosclerosis in the clinic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-022-00955-7

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inflammation is critically implicated in the pathogenesis and progression of numerous diseases.

    “Inflammation, as a basic pathological process, is critically implicated in the pathogenesis and progression of numerous diseases.”

    From Picroside II as a Potential Anti-Inflammatory Agent (2026) · cites this paper as [4]

    The Introduction identifies atherosclerosis as chronic vascular inflammation and describes inflammatory processes that promote plaque progression. The paper supports the claim for atherosclerosis, but the broader assertion about the pathogenesis and progression of numerous diseases is not established by these passages. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 345

  1. [1]Basatemur, G. L. et al. Vascular smooth muscle cells in atherosclerosis. Nat. Rev. Cardiol.16, 727–744 (2019). 31243391
  2. [2]Soehnlein O Libby P Targeting inflammation in atherosclerosis - from experimental insights to the clinic Nat. Rev. Drug Discov. 2021 20 589 610 10.1038/s41573-021-00198-1 33976384 PMC8112476 · DOI
  3. [3]Roy, P., Orecchioni, M. & Ley, K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat. Rev. Immunol. (2021). [Online ahead of print] PMC10111155 34389841
  4. [4]Hansson GK Hermansson A The immune system in atherosclerosis Nat. Immunol. 2011 12 204 212 10.1038/ni.2001 21321594 · DOI
  5. [5]Ilatovskaya DV Halade GV DeLeon-Pennell KY Adaptive immunity-driven inflammation and cardiovascular disease Am. J. Physiol. Heart Circ. Physiol. 2019 317 H1254 H1257 10.1152/ajpheart.00642.2019 31702971 PMC6960777 · DOI
  6. [6]Jaipersad AS Lip GY Silverman S Shantsila E The role of monocytes in angiogenesis and atherosclerosis J. Am. Coll. Cardiol. 2014 63 1 11 10.1016/j.jacc.2013.09.019 24140662 · DOI
  7. [7]Ross R Atherosclerosis–an inflammatory disease N. Engl. J. Med. 1999 340 115 126 10.1056/NEJM199901143400207 9887164 · DOI · Paper page
  8. [8]Wolf D Ley K Immunity and Inflammation in Atherosclerosis Circ. Res. 2019 124 315 327 10.1161/CIRCRESAHA.118.313591 30653442 PMC6342482 · DOI
  9. [9]Miller YI Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity Circ. Res. 2011 108 235 248 10.1161/CIRCRESAHA.110.223875 21252151 PMC3075542 · DOI
  10. [10]Tabas I Macrophage death and defective inflammation resolution in atherosclerosis Nat. Rev. Immunol. 2010 10 36 46 10.1038/nri2675 19960040 PMC2854623 · DOI · Paper page
  11. [11]Fernandez DM Single-cell immune landscape of human atherosclerotic plaques Nat. Med. 2019 25 1576 1588 10.1038/s41591-019-0590-4 31591603 PMC7318784 · DOI · Paper page
  12. [12]Bornfeldt KE Linton MF Fisher EA Guyton JR JCL roundtable: lipids and inflammation in atherosclerosis J. Clin. Lipido. 2021 15 3 17 10.1016/j.jacl.2021.01.005 PMC10009885 33589093 · DOI
  13. [13]Mauricio D Castelblanco E Alonso N Cholesterol and Inflammation in atherosclerosis: an immune-metabolic hypothesis Nutrients 2020 12 2444 10.3390/nu12082444 PMC7468975 32823869 · DOI
  14. [14]Libby P Inflammation in atherosclerosis-no longer a theory Clin. Chem. 2021 67 131 142 10.1093/clinchem/hvaa275 33393629 · DOI
  15. [15]Jinagal J Dhiman P Retraction: retinal hemorrhage from blunt ocular trauma N. Engl. J. Med. 2019 382 490 10.1056/NEJMc1917339 31800990 · DOI
  16. [16]Clark, B. C. & Arnold, W. D. Strategies to prevent serious fall injuries: a commentary on bhasin et al. a randomized trial of a multifactorial strategy to prevent serious fall injuries. Adv. Geriatr. Med. Res.3, e210002 (2021). PMC7710184 33283207
  17. [17]Shao C Wang J Tian J Tang YD Coronary artery disease: from mechanism to clinical practice Adv. Exp. Med. Biol. 2020 1177 1 36 10.1007/978-981-15-2517-9_1 32246442 · DOI
  18. [19]Lei W MARCH5 restores endothelial cell function against ischaemic/hypoxia injury via Akt/eNOS pathway J. Cell. Mol. Med. 2021 25 3182 3193 10.1111/jcmm.16386 33611830 PMC8034466 · DOI
  19. [20]Siragusa M VE-PTP inhibition elicits eNOS phosphorylation to blunt endothelial dysfunction and hypertension in diabetes Cardiovasc. Res. 2021 117 1546 1556 10.1093/cvr/cvaa213 32653904 · DOI
  20. [21]Tajadura V beta-catenin promotes endothelial survival by regulating eNOS activity and flow-dependent anti-apoptotic gene expression Cell Death Dis. 2020 11 493 10.1038/s41419-020-2687-6 32606304 PMC7326989 · DOI
  21. [22]Raina P Association of eNOS and MCP-1 genetic variants with type 2 diabetes and diabetic nephropathy susceptibility: a case-control and meta-analysis study Biochem Genet 2021 59 966 996 10.1007/s10528-021-10041-2 33609191 PMC7896546 · DOI
  22. [23]Dobnikar L Disease-relevant transcriptional signatures identified in individual smooth muscle cells from healthy mouse vessels Nat. Commun. 2018 9 4567 10.1038/s41467-018-06891-x 30385745 PMC6212435 · DOI
  23. [24]Kaur H Single-cell profiling reveals heterogeneity and functional patterning of GPCR expression in the vascular system Nat. Commun. 2017 8 15700 10.1038/ncomms15700 28621310 PMC5481776 · DOI
  24. [25]Kapustin AN Vascular smooth muscle cell calcification is mediated by regulated exosome secretion Circ. Res 2015 116 1312 1323 10.1161/CIRCRESAHA.116.305012 25711438 · DOI · Paper page
  25. [26]Furmanik M Endoplasmic reticulum stress mediates vascular smooth muscle cell calcification via increased release of Grp78 (glucose-regulated protein, 78 kDa)-loaded extracellular vesicles Arterioscler. Thromb. Vasc. Biol. 2021 41 898 914 10.1161/ATVBAHA.120.315506 33297752 PMC7837691 · DOI
  26. [27]Owens AP 3rd Angiotensin II induces a region-specific hyperplasia of the ascending aorta through regulation of inhibitor of differentiation 3 Circ. Res. 2010 106 611 619 10.1161/CIRCRESAHA.109.212837 20019328 PMC2825288 · DOI
  27. [28]Alencar GF Stem cell pluripotency genes Klf4 and Oct4 regulate complex SMC phenotypic changes critical in late-stage atherosclerotic lesion pathogenesis Circulation 2020 142 2045 2059 10.1161/CIRCULATIONAHA.120.046672 32674599 PMC7682794 · DOI
  28. [29]Hong X Transdifferentiated Human Vascular Smooth Muscle Cells are a New Potential Cell Source for Endothelial Regeneration Sci. Rep. 2017 7 5590 10.1038/s41598-017-05665-7 28717251 PMC5514066 · DOI
  29. [30]Davies JD Adipocytic differentiation and liver x receptor pathways regulate the accumulation of triacylglycerols in human vascular smooth muscle cells J. Biol. Chem. 2005 280 3911 3919 10.1074/jbc.M410075200 15548517 · DOI
  30. [31]Pan H Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human Circulation 2020 142 2060 2075 10.1161/CIRCULATIONAHA.120.048378 32962412 PMC8104264 · DOI
  31. [32]Han, M. et al. Serum deprivation results in redifferentiation of human umbilical vascular smooth muscle cells. Am. J. Physiol. Cell. Physiol.291, C50–C58 (2006). 16467401
  32. [33]Grootaert MOJ Bennett MR Vascular smooth muscle cells in atherosclerosis: time for a re-assessment Cardiovasc. Res. 2021 117 2326 2339 10.1093/cvr/cvab046 33576407 PMC8479803 · DOI
  33. [34]Vengrenyuk Y Cholesterol loading reprograms the microRNA-143/145-myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype Arterioscler. Thromb. Vasc. Biol. 2015 35 535 546 10.1161/ATVBAHA.114.304029 25573853 PMC4344402 · DOI · Paper page
  34. [35]Shankman LS KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis Nat. Med. 2015 21 628 637 10.1038/nm.3866 25985364 PMC4552085 · DOI · Paper page
  35. [36]Mattila PK Batista FD Treanor B Dynamics of the actin cytoskeleton mediates receptor cross talk: an emerging concept in tuning receptor signaling J. Cell Biol. 2016 212 267 280 10.1083/jcb.201504137 26833785 PMC4748574 · DOI
  36. [37]Solway J Structure and expression of a smooth muscle cell-specific gene, SM22 alpha J. Biol. Chem. 1995 270 13460 13469 10.1074/jbc.270.22.13460 7768949 · DOI
  37. [38]Han M Smooth muscle 22 alpha maintains the differentiated phenotype of vascular smooth muscle cells by inducing filamentous actin bundling Life Sci. 2009 84 394 401 10.1016/j.lfs.2008.11.017 19073196 · DOI
  38. [39]Liu R Hossain MM Chen X Jin JP Mechanoregulation of SM22alpha/transgelin Biochemistry 2017 56 5526 5538 10.1021/acs.biochem.7b00794 28898058 · DOI
  39. [40]Xie XL Smooth muscle 22alpha facilitates angiotensin II-induced signaling and vascular contraction J. Mol. Med. 2015 93 547 558 10.1007/s00109-014-1240-4 25515236 · DOI
  40. [41]Shu YN CKII-SIRT1-SM22alpha loop evokes a self-limited inflammatory response in vascular smooth muscle cells Cardiovasc. Res. 2017 113 1198 1207 10.1093/cvr/cvx048 28419207 · DOI
  41. [42]Shu YN SM22alpha inhibits vascular inflammation via stabilization of IkappaBalpha in vascular smooth muscle cells J. Mol. Cell Cardiol. 2015 84 191 199 10.1016/j.yjmcc.2015.04.020 25937534 · DOI
  42. [43]Hu, D. et al. Vascular smooth muscle cells contribute to atherosclerosis immunity. Front. Immunol.10, 1101 (2019). PMC6534067 31164888
  43. [44]Lv P SM22alpha loss contributes to apoptosis of vascular smooth muscle cells via macrophage-derived circRasGEF1B Oxid. Med Cell Longev. 2021 2021 5564884 33859778 PMC8026322
  44. [45]Zhong L SM22alpha (smooth Muscle 22alpha) prevents aortic aneurysm formation by inhibiting smooth muscle cell phenotypic switching through suppressing reactive oxygen species/nf-kappab (nuclear factor-kappaB) Arterioscler. Thromb. Vasc. Biol. 2019 39 e10 e25 10.1161/ATVBAHA.118.311917 30580562 · DOI · Paper page
  45. [46]Chen R Transcriptome profiling reveals that the SM22alpha-regulated molecular pathways contribute to vascular pathology J. Mol. Cell Cardiol. 2014 72 263 272 10.1016/j.yjmcc.2014.04.003 24735829 · DOI
  46. [47]Dong LH Blockade of the Ras-extracellular signal-regulated kinase 1/2 pathway is involved in smooth muscle 22 alpha-mediated suppression of vascular smooth muscle cell proliferation and neointima hyperplasia Arterioscler. Thromb. Vasc. Biol. 2010 30 683 691 10.1161/ATVBAHA.109.200501 20139360 · DOI
  47. [48]Lv P SM22alpha inhibits lamellipodium formation and migration via Ras-Arp2/3 signaling in synthetic VSMCs Am. J. Physiol. Cell Physiol. 2016 311 C758 C767 10.1152/ajpcell.00033.2016 27629412 · DOI
  48. [49]Lv P Phosphorylation of smooth muscle 22alpha facilitates angiotensin II-induced ROS production via activation of the PKCdelta-P47phox axis through release of PKCdelta and actin dynamics and is associated with hypertrophy and hyperplasia of vascular smooth muscle cells in vitro and in vivo Circ. Res. 2012 111 697 707 10.1161/CIRCRESAHA.112.272013 22798525 · DOI
  49. [50]Zhao LL Insulin-independent GLUT4 translocation in proliferative vascular smooth muscle cells involves SM22alpha J. Mol. Med. 2017 95 181 192 10.1007/s00109-016-1468-2 27631639 · DOI
  50. [51]Dong LH TRAF6-mediated SM22alpha K21 ubiquitination promotes G6PD activation and NADPH production, contributing to GSH homeostasis and VSMC survival in vitro and in vivo Circ. Res 2015 117 684 694 10.1161/CIRCRESAHA.115.306233 26291555 · DOI
  51. [52]Zhang DD Smooth muscle 22 alpha protein inhibits VSMC foam cell formation by supporting normal LXRalpha signaling, ameliorating atherosclerosis Cell Death Dis. 2021 12 982 10.1038/s41419-021-04239-w 34686657 PMC8536684 · DOI
  52. [53]Miao SB Accumulation of smooth muscle 22alpha protein accelerates senescence of vascular smooth muscle cells via stabilization of p53 In Vitro and In Vivo Arterioscler. Thromb. Vasc. Biol. 2017 37 1849 1859 10.1161/ATVBAHA.117.309378 28798142 · DOI
  53. [54]Serpa PBS Santos AP Incidental diagnosis of a spindle cell type gastrointestinal stromal tumor in a dog with ethylene glycol intoxication Vet. Clin. Pathol. 2021 50 70 75 10.1111/vcp.13063 34806207 · DOI
  54. [55]Richardson A Ganz O Vallone D The cigar ambassador: how Snoop Dogg uses instagram to promote tobacco use Tob. Control 2014 23 79 80 10.1136/tobaccocontrol-2013-051037 23748187 · DOI
  55. [56]Tinajero MG Gotlieb AI Recent developments in vascular adventitial pathobiology: the dynamic adventitia as a complex regulator of vascular disease Am. J. Pathol. 2020 190 520 534 10.1016/j.ajpath.2019.10.021 31866347 · DOI
  56. [57]Lordan R Tsoupras A Zabetakis I Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents Blood Rev. 2021 45 100694 10.1016/j.blre.2020.100694 32340775 · DOI
  57. [58]Ed Rainger G The role of platelets in the recruitment of leukocytes during vascular disease Platelets 2015 26 507 520 10.3109/09537104.2015.1064881 26196409 PMC4673595 · DOI
  58. [59]van der Pol, E. et al. Classification, functions, and clinical relevance of extracellular vesicles. Pharm. Rev.64, 676–705 (2012). 22722893
  59. [60]Lee MKS Apoptotic ablation of platelets reduces atherosclerosis in mice with diabetes Arterioscler. Thromb. Vasc. Biol. 2021 41 1167 1178 10.1161/ATVBAHA.120.315369 33441028 PMC7904582 · DOI
  60. [61]Theofilis P Inflammatory mediators of platelet activation: focus on atherosclerosis and COVID-19 Int. J. Mol. Sci. 2021 22 11170 10.3390/ijms222011170 34681830 PMC8539848 · DOI
  61. [62]Robbins CS Local proliferation dominates lesional macrophage accumulation in atherosclerosis Nat. Med. 2013 19 1166 1172 10.1038/nm.3258 23933982 PMC3769444 · DOI · Paper page
  62. [63]Barrett TJ Macrophages in atherosclerosis regression Arterioscler. Thromb. Vasc. Biol. 2020 40 20 33 10.1161/ATVBAHA.119.312802 31722535 PMC6946104 · DOI
  63. [64]Khoury MK Yang H Liu B Macrophage biology in cardiovascular diseases Arterioscler. Thromb. Vasc. Biol. 2021 41 e77 e81 10.1161/ATVBAHA.120.313584 33054391 PMC8046835 · DOI
  64. [66]Boyle JJ Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection Circ. Res. 2012 110 20 33 10.1161/CIRCRESAHA.111.247577 22052915 · DOI
  65. [67]Maretti-Mira, A. C. et al. Cholesterol-induced M4-like macrophages recruit neutrophils and induce NETosis. Front. Immunol.12, 671073 (2021). PMC8126646 34012454
  66. [68]Yin C Efferocytic defects in early atherosclerosis are driven by GATA2 overexpression in macrophages Front. Immunol. 2020 11 594136 10.3389/fimmu.2020.594136 33193444 PMC7644460 · DOI
  67. [69]Lavin Y Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment Cell 2014 159 1312 1326 10.1016/j.cell.2014.11.018 25480296 PMC4437213 · DOI · Paper page
  68. [70]X. Huang, et al. Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages. Nat. Protoc. (2022). [Online ahead of print]. PMC9734002 35121853
  69. [71]W. Chen, et al. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat. Rev. Cardiol. (2021). [Online ahead of print]. PMC8580169 34759324
  70. [72]Tao W siRNA nanoparticles targeting CaMKIIgamma in lesional macrophages improve atherosclerotic plaque stability in mice Sci. Transl. Med. 2020 12 1063 10.1126/scitranslmed.aay1063 PMC7476570 32718990 · DOI
  71. [73]Yurdagul A Jr ODC (ornithine decarboxylase)-dependent putrescine synthesis maintains MerTK (MER tyrosine-protein kinase) expression to drive resolution Arterioscler. Thromb. Vasc. Biol. 2021 41 e144 e159 10.1161/ATVBAHA.120.315622 33406854 PMC8034502 · DOI
  72. [74]Dworacka M Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients Circ. J. 2007 71 962 967 10.1253/circj.71.962 17526997 · DOI
  73. [75]Nunez J Low lymphocyte count and cardiovascular diseases Curr. Med. Chem. 2011 18 3226 3233 10.2174/092986711796391633 21671854 · DOI
  74. [76]Tyrrell DJ Goldstein DR Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6 Nat. Rev. Cardiol. 2021 18 58 68 10.1038/s41569-020-0431-7 32918047 PMC7484613 · DOI
  75. [77]Sekiya T Yoshimura A In vitro Th differentiation protocol Methods Mol. Biol. 2016 1344 183 191 10.1007/978-1-4939-2966-5_10 26520124 · DOI
  76. [78]Buono C T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses Proc. Natl. Acad. Sci. USA 2005 102 1596 1601 10.1073/pnas.0409015102 15665085 PMC547865 · DOI
  77. [79]Wigren M Nilsson J Kolbus D Lymphocytes in atherosclerosis Clin. Chim. Acta 2012 413 1562 1568 10.1016/j.cca.2012.04.031 22565046 · DOI
  78. [80]Saigusa R Winkels H Ley K T cell subsets and functions in atherosclerosis Nat. Rev. Cardiol. 2020 17 387 401 10.1038/s41569-020-0352-5 32203286 PMC7872210 · DOI
  79. [81]Milner JD Sandler NG Douek DC Th17 cells, Job’s syndrome and HIV: opportunities for bacterial and fungal infections Curr. Opin. HIV AIDS 2010 5 179 183 10.1097/COH.0b013e328335ed3e 20543597 PMC4485419 · DOI
  80. [82]Smith E Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice Circulation 2010 121 1746 1755 10.1161/CIRCULATIONAHA.109.924886 20368519 PMC2929562 · DOI
  81. [83]Madhur MS Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice Arterioscler. Thromb. Vasc. Biol. 2011 31 1565 1572 10.1161/ATVBAHA.111.227629 21474820 PMC3117048 · DOI
  82. [84]Taleb S Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis J. Exp. Med. 2009 206 2067 2077 10.1084/jem.20090545 19737863 PMC2757872 · DOI
  83. [85]Veillard, N. R. et al. Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler. Thromb. Vasc. Biol.24, 2339–2344 (2004). 15458979
  84. [86]Ley K Role of the adaptive immune system in atherosclerosis Biochem. Soc. Trans. 2020 48 2273 2281 10.1042/BST20200602 32869829 PMC7863745 · DOI
  85. [87]Bonacina F Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression Cardiovasc. Res. 2021 117 2069 2082 10.1093/cvr/cvaa264 32931583 · DOI
  86. [88]Xia M Wu Q Chen P Qian C Regulatory T cell-related gene biomarkers in the deterioration of atherosclerosis Front. Cardiovasc. Med. 2021 8 661709 10.3389/fcvm.2021.661709 34095251 PMC8172618 · DOI
  87. [89]Winkels H Wolf D Heterogeneity of T cells in atherosclerosis defined by single-cell RNA-sequencing and cytometry by time of flight Arterioscler. Thromb. Vasc. Biol. 2021 41 549 563 10.1161/ATVBAHA.120.312137 33267666 PMC7837690 · DOI
  88. [90]Schafer S Zernecke A CD8(+) T cells in atherosclerosis Cells 2020 10 37 10.3390/cells10010037 PMC7823404 33383733 · DOI
  89. [91]van Duijn J CD8+ T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T-cell responses Cardiovasc. Res. 2019 115 729 738 10.1093/cvr/cvy261 30335148 · DOI
  90. [92]Amirfakhryan H Vaccination against atherosclerosis: an overview Hellenic J. Cardiol. 2020 61 78 91 10.1016/j.hjc.2019.07.003 31352027 · DOI
  91. [93]Back M Yurdagul A Jr Tabas I Oorni K Kovanen PT Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities Nat. Rev. Cardiol. 2019 16 389 406 30846875 PMC6727648
  92. [94]Aguilar-Ballester, M. et al. Impact of cholesterol metabolism in immune cell function and atherosclerosis. Nutrients12, 2021 (2020). PMC7400846 32645995
  93. [95]Tsiantoulas D Sage AP Mallat Z Binder CJ Targeting B cells in atherosclerosis: closing the gap from bench to bedside Arterioscler. Thromb. Vasc. Biol. 2015 35 296 302 10.1161/ATVBAHA.114.303569 25359862 · DOI
  94. [96]Mangge, H. et al. Beyond macrophages and T cells: B cells and immunoglobulins determine the fate of the atherosclerotic plaque. Int. J. Mol. Sci.21, 4082 (2020). PMC7312004 32521607
  95. [97]Fillatreau, S. et al. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol.3, 944–950 (2002). 12244307
  96. [98]Blair PA CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients Immunity 2010 32 129 140 10.1016/j.immuni.2009.11.009 20079667 · DOI · Paper page
  97. [99]Rincon-Arevalo H Low frequency of IL-10(+) B cells in patients with atherosclerosis is related with inflammatory condition Heliyon 2020 6 e03441 10.1016/j.heliyon.2020.e03441 32154409 PMC7057201 · DOI
  98. [100]Kyaw T Alarmin-activated B cells accelerate murine atherosclerosis after myocardial infarction via plasma cell-immunoglobulin-dependent mechanisms Eur. Heart J. 2021 42 938 947 10.1093/eurheartj/ehaa995 33338208 · DOI
  99. [101]Quillard T TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion Eur. Heart J. 2015 36 1394 1404 10.1093/eurheartj/ehv044 25755115 PMC4458287 · DOI
  100. [102]Franck G Flow perturbation mediates neutrophil recruitment and potentiates endothelial injury via TLR2 in mice: implications for superficial erosion Circ. Res. 2017 121 31 42 10.1161/CIRCRESAHA.117.310694 28428204 PMC5488735 · DOI
  101. [103]Pieterse, E. et al. Neutrophils discriminate between lipopolysaccharides of different bacterial sources and selectively release neutrophil extracellular traps. Front. Immunol.7, 484 (2016). PMC5095130 27867387
  102. [104]Nahrendorf M Swirski FK Immunology. Neutrophil-macrophage communication in inflammation and atherosclerosis Science 2015 349 237 238 10.1126/science.aac7801 26185231 · DOI
  103. [105]T. Josefs, et al. Neutrophil extracellular traps promote macrophage inflammation and impair atherosclerosis resolution in diabetic mice. JCI Insight.5, e134796 (2020). PMC7205252 32191637
  104. [106]Doring Y Libby P Soehnlein O Neutrophil extracellular traps participate in cardiovascular diseases: recent experimental and clinical insights Circ. Res. 2020 126 1228 1241 10.1161/CIRCRESAHA.120.315931 32324499 PMC7185047 · DOI
  105. [107]Schumski A Endotoxinemia accelerates atherosclerosis through electrostatic charge-mediated monocyte adhesion Circulation 2021 143 254 266 10.1161/CIRCULATIONAHA.120.046677 33167684 PMC7914394 · DOI
  106. [108]Hermans M Lennep JRV van Daele P Bot I Mast cells in cardiovascular disease: from bench to bedside Int. J. Mol. Sci. 2019 20 3395 10.3390/ijms20143395 PMC6678575 31295950 · DOI
  107. [109]Kouhpeikar H The effect of statins through mast cells in the pathophysiology of atherosclerosis: a review Curr. Atheroscler. Rep. 2020 22 19 10.1007/s11883-020-00837-9 32458165 · DOI
  108. [110]Lee, M. et al. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol.22, 1475–1481 (2002). 12231569
  109. [111]Dounousi, E. et al. The innate immune system and cardiovascular disease in ESKD: monocytes and natural killer cells. Curr. Vasc. Pharm.19, 63–76 (2021). 32600233
  110. [112]Le Bouteiller P CD160: a unique activating NK cell receptor Immunol. Lett. 2011 138 93 96 10.1016/j.imlet.2011.02.003 21324341 · DOI
  111. [113]Bonaccorsi I Symptomatic carotid atherosclerotic plaques are associated with increased infiltration of natural killer (NK) cells and higher serum levels of NK activating receptor ligands Front. Immunol. 2019 10 1503 10.3389/fimmu.2019.01503 31354703 PMC6639781 · DOI
  112. [114]Nour-Eldine W Genetic depletion or hyperresponsiveness of natural killer cells do not affect atherosclerosis development Circ. Res. 2018 122 47 57 10.1161/CIRCRESAHA.117.311743 29046274 · DOI
  113. [115]Li Y Natural killer cells: friend or foe in metabolic diseases? Front Immunol. 2021 12 614429 10.3389/fimmu.2021.614429 33717101 PMC7943437 · DOI
  114. [116]Zhao Y Zhang J Zhang W Xu Y A myriad of roles of dendritic cells in atherosclerosis Clin. Exp. Immunol. 2021 206 12 27 10.1111/cei.13634 34109619 PMC8446417 · DOI
  115. [117]Clement M Impaired autophagy in CD11b(+) dendritic cells expands CD4(+) regulatory T cells and limits atherosclerosis in mice Circ. Res. 2019 125 1019 1034 10.1161/CIRCRESAHA.119.315248 31610723 PMC6844650 · DOI · Paper page
  116. [118]Sun Y Alisol B 23-acetate, a new promoter for cholesterol efflux from dendritic cells, alleviates dyslipidemia and inflammation in advanced atherosclerotic mice Int. Immunopharmacol. 2021 99 107956 10.1016/j.intimp.2021.107956 34284288 · DOI
  117. [119]Wang Y Song E Bai B Vanhoutte PM Toll-like receptors mediating vascular malfunction: lessons from receptor subtypes Pharm. Ther. 2016 158 91 100 10.1016/j.pharmthera.2015.12.005 26702901 · DOI
  118. [120]Mann DL The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls Circ. Res. 2011 108 1133 1145 10.1161/CIRCRESAHA.110.226936 21527743 PMC3084988 · DOI
  119. [121]Beutler B Inferences, questions and possibilities in Toll-like receptor signalling Nature 2004 430 257 263 10.1038/nature02761 15241424 · DOI
  120. [123]Lee CC Avalos AM Ploegh HL Accessory molecules for Toll-like receptors and their function Nat. Rev. Immunol. 2012 12 168 179 10.1038/nri3151 22301850 PMC3677579 · DOI
  121. [125]Lee JY Hwang DH The modulation of inflammatory gene expression by lipids: mediation through toll-like receptors Mol. Cells 2006 21 174 185 16682810
  122. [126]Lee JY Zhao L Hwang DH Modulation of pattern recognition receptor-mediated inflammation and risk of chronic diseases by dietary fatty acids Nutr. Rev. 2010 68 38 61 10.1111/j.1753-4887.2009.00259.x 20041999 · DOI
  123. [127]Peiser L Mukhopadhyay S Gordon S Scavenger receptors in innate immunity Curr. Opin. Immunol. 2002 14 123 128 10.1016/S0952-7915(01)00307-7 11790542 · DOI
  124. [128]Miller YI Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages Arterioscler. Thromb. Vasc. Biol. 2005 25 1213 1219 10.1161/01.ATV.0000159891.73193.31 15718493 · DOI
  125. [129]Bhaskar S Sudhakaran PR Helen A Quercetin attenuates atherosclerotic inflammation and adhesion molecule expression by modulating TLR-NF-kappaB signaling pathway Cell Immunol. 2016 310 131 140 10.1016/j.cellimm.2016.08.011 27585526 · DOI
  126. [130]Curtiss LK Black AS Bonnet DJ Tobias PS Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists J. Lipid. Res. 2012 53 2126 2132 10.1194/jlr.M028431 22822027 PMC3435545 · DOI
  127. [131]Roshan MH Tambo A Pace NP The role of TLR2, TLR4, and TLR9 in the pathogenesis of atherosclerosis Int J. Inflam. 2016 2016 1532832 27795867 PMC5067326
  128. [132]Kim J The flagellin-TLR5-Nox4 axis promotes the migration of smooth muscle cells in atherosclerosis Exp. Mol. Med. 2019 51 1 13 31292433 PMC6802658
  129. [133]Kapelouzou A Overexpression of toll-like receptors 2, 3, 4, and 8 is correlated to the vascular atherosclerotic process in the hyperlipidemic rabbit model: the effect of statin treatment J. Vasc. Res. 2017 54 156 169 10.1159/000457797 28478461 · DOI
  130. [134]Fukuda D Toll-like receptor 9 plays a pivotal role in angiotensin II-induced therosclerosis J. Am. Heart Assoc. 2019 8 e010860 10.1161/JAHA.118.010860 30905257 PMC6509720 · DOI
  131. [135]Li B Xia Y Hu B Infection and atherosclerosis: TLR-dependent pathways Cell Mol. Life Sci. 2020 77 2751 2769 10.1007/s00018-020-03453-7 32002588 PMC7223178 · DOI
  132. [137]Ding Y Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice Arterioscler. Thromb. Vasc. Biol. 2012 32 1596 1604 10.1161/ATVBAHA.112.249847 22580897 PMC3748807 · DOI
  133. [138]Bayer AL Alcaide P MyD88: at the heart of inflammatory signaling and cardiovascular disease J. Mol. Cell Cardiol. 2021 161 75 85 10.1016/j.yjmcc.2021.08.001 34371036 PMC8629847 · DOI
  134. [139]Geng, S. et al. Resolving monocytes generated through TRAM deletion attenuate atherosclerosis. JCI Insight.6, e149651 (2021). PMC8564896 34499622
  135. [140]Huang B Park DW Baek SH TRIF is a regulator of TLR2-induced foam cell formation Mol. Med. Rep. 2016 14 3329 3335 10.3892/mmr.2016.5647 27572666 · DOI
  136. [141]Yin QY Research progress of mechanisms and drug therapy for atherosclerosis on toll-like receptor pathway J. Cardiovasc. Pharm. 2019 74 379 388 10.1097/FJC.0000000000000738 31730559 · DOI
  137. [142]Lehr HA Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet Circulation 2001 104 914 920 10.1161/hc3401.093153 11514379 · DOI
  138. [143]Bahrami, A. et al. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharm. Res.135, 230–238 (2018). 30120976
  139. [144]Lu, Z. et al. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice. J. Endocrinol.216, 61–71 (2013). 23060524
  140. [145]Monaco C Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis Circulation 2009 120 2462 2469 10.1161/CIRCULATIONAHA.109.851881 19948979 · DOI
  141. [146]Miyamoto T Pathogen-accelerated atherosclerosis occurs early after exposure and can be prevented via immunization Infect. Immun. 2006 74 1376 1380 10.1128/IAI.74.2.1376-1380.2006 16428788 PMC1360301 · DOI
  142. [147]Binder CJ Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL Nat. Med. 2003 9 736 743 10.1038/nm876 12740573 · DOI
  143. [148]Pothineni NVK Infections, atherosclerosis, and coronary heart disease Eur. Heart J. 2017 38 3195 3201 10.1093/eurheartj/ehx362 29020241 · DOI
  144. [149]Shah PK Chyu KY Dimayuga PC Nilsson J Vaccine for atherosclerosis J. Am. Coll. Cardiol. 2014 64 2779 2791 10.1016/j.jacc.2014.10.018 25541132 · DOI
  145. [150]Sharma BR Kanneganti TD NLRP3 inflammasome in cancer and metabolic diseases Nat. Immunol. 2021 22 550 559 10.1038/s41590-021-00886-5 33707781 PMC8132572 · DOI
  146. [151]Liaqat A Asad M Shoukat F Khan AU A spotlight on the underlying activation mechanisms of the NLRP3 inflammasome and its role in atherosclerosis: a review Inflammation 2020 43 2011 2020 10.1007/s10753-020-01290-1 32656610 · DOI
  147. [152]Jin Y Fu J Novel insights into the NLRP 3 inflammasome in atherosclerosis J. Am. Heart Assoc. 2019 8 e012219 10.1161/JAHA.119.012219 31184236 PMC6645652 · DOI
  148. [153]M. Takahashi. NLRP3 inflammasome as a key driver of vascular disease. Cardiovasc. Res.118, 372–385 (2021). 33483732
  149. [154]F. Burger, et al. NLRP3 inflammasome activation controls vascular smooth muscle cells phenotypic switch in atherosclerosis. Int. J. Mol. Sci.23, 340 (2021). PMC8745068 35008765
  150. [155]Duncan JA Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling Proc. Natl. Acad. Sci. USA 2007 104 8041 8046 10.1073/pnas.0611496104 17483456 PMC1876568 · DOI
  151. [156]Vajjhala PR Mirams RE Hill JM Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein J. Biol. Chem. 2012 287 41732 41743 10.1074/jbc.M112.381228 23066025 PMC3516722 · DOI
  152. [157]Yu HB Finlay BB The caspase-1 inflammasome: a pilot of innate immune responses Cell Host Microbe 2008 4 198 208 10.1016/j.chom.2008.08.007 18779046 · DOI
  153. [158]Christgen S Kanneganti TD Inflammasomes and the fine line between defense and disease Curr. Opin. Immunol. 2020 62 39 44 10.1016/j.coi.2019.11.007 31837596 PMC7067632 · DOI
  154. [159]Christgen S Place DE Kanneganti TD Toward targeting inflammasomes: insights into their regulation and activation Cell Res. 2020 30 315 327 10.1038/s41422-020-0295-8 32152420 PMC7118104 · DOI
  155. [160]Sheedy FJ CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation Nat. Immunol. 2013 14 812 820 10.1038/ni.2639 23812099 PMC3720827 · DOI · Paper page
  156. [164]Yi YS Caspase-11 non-canonical inflammasome: a critical sensor of intracellular lipopolysaccharide in macrophage-mediated inflammatory responses Immunology 2017 152 207 217 10.1111/imm.12787 28695629 PMC5588777 · DOI
  157. [165]Shi J Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death Nature 2015 526 660 665 10.1038/nature15514 26375003 · DOI · Paper page
  158. [166]Kayagaki N Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling Nature 2015 526 666 671 10.1038/nature15541 26375259 · DOI · Paper page
  159. [167]Zeng C Wang R Tan H Role of pyroptosis in cardiovascular diseases and its therapeutic implications Int. J. Biol. Sci. 2019 15 1345 1357 10.7150/ijbs.33568 31337966 PMC6643148 · DOI
  160. [168]Yang, D. et al. Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock. Immunity43, 923–932 (2015). PMC4795157 26572062
  161. [169]Seok, J. K. et al. Regulation of the NLRP3 inflammasome by post-translational modifications and small molecules. Front. Immunol.11, 618231 (2020). PMC7884467 33603747
  162. [170]Gaidt MM Human monocytes engage an alternative inflammasome pathway Immunity 2016 44 833 846 10.1016/j.immuni.2016.01.012 27037191 · DOI
  163. [171]Karki, R. et al. IRF8 regulates gram-negative bacteria-mediated NLRP3 inflammasome activation and cell death. J. Immunol.204, 2514–2522 (2020). PMC7291389 32205422
  164. [172]Gurung P Toll or interleukin-1 receptor (TIR) domain-containing adaptor inducing interferon-beta (TRIF)-mediated caspase-11 protease production integrates Toll-like receptor 4 (TLR4) protein- and Nlrp3 inflammasome-mediated host defense against enteropathogens J. Biol. Chem. 2012 287 34474 34483 10.1074/jbc.M112.401406 22898816 PMC3464552 · DOI
  165. [173]Gurung P FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes J. Immunol. 2014 192 1835 1846 10.4049/jimmunol.1302839 24453255 PMC3933570 · DOI
  166. [174]Samir P DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome Nature 2019 573 590 594 10.1038/s41586-019-1551-2 31511697 PMC6980284 · DOI
  167. [175]Vande L Walle, et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis Nature 2014 512 69 73 10.1038/nature13322 25043000 PMC4126806 · DOI
  168. [176]Malireddi RKS TAK1 restricts spontaneous NLRP3 activation and cell death to control myeloid proliferation J. Exp. Med 2018 215 1023 1034 10.1084/jem.20171922 29500178 PMC5881469 · DOI
  169. [177]Briard B Galactosaminogalactan activates the inflammasome to provide host protection Nature 2020 588 688 692 10.1038/s41586-020-2996-z 33268895 PMC8086055 · DOI
  170. [178]Sharif H Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome Nature 2019 570 338 343 10.1038/s41586-019-1295-z 31189953 PMC6774351 · DOI · Paper page
  171. [179]Swanson KV Deng M Ting JP The NLRP3 inflammasome: molecular activation and regulation to therapeutics Nat. Rev. Immunol. 2019 19 477 489 10.1038/s41577-019-0165-0 31036962 PMC7807242 · DOI · Paper page
  172. [180]Song H The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3 Nat. Commun. 2016 7 13727 10.1038/ncomms13727 27929086 PMC5155141 · DOI
  173. [181]Barry R SUMO-mediated regulation of NLRP3 modulates inflammasome activity Nat. Commun. 2018 9 3001 10.1038/s41467-018-05321-2 30069026 PMC6070540 · DOI
  174. [182]Shao L SUMO1 SUMOylates and SENP3 deSUMOylates NLRP3 to orchestrate the inflammasome activation FASEB J. 2020 34 1497 1515 10.1096/fj.201901653R 31914638 · DOI
  175. [183]Zheng D Liwinski T Elinav E Inflammasome activation and regulation: toward a better understanding of complex mechanisms Cell Discov. 2020 6 36 10.1038/s41421-020-0167-x 32550001 PMC7280307 · DOI
  176. [184]Martinez GJ Celermajer DS Patel S The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation Atherosclerosis 2018 269 262 271 10.1016/j.atherosclerosis.2017.12.027 29352570 · DOI
  177. [185]Yajima N Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice Circulation 2008 117 3079 3087 10.1161/CIRCULATIONAHA.107.746453 18541743 · DOI
  178. [189]Menu P Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome Cell Death Dis. 2011 2 e137 10.1038/cddis.2011.18 21451572 PMC3101814 · DOI
  179. [190]Chen S Sex-specific effects of the Nlrp3 inflammasome on atherogenesis in LDL receptor-deficient mice JACC Basic Transl. Sci. 2020 5 582 598 10.1016/j.jacbts.2020.03.016 32613145 PMC7315187 · DOI
  180. [191]Hoseini Z NLRP3 inflammasome: its regulation and involvement in atherosclerosis J. Cell Physiol. 2018 233 2116 2132 10.1002/jcp.25930 28345767 · DOI
  181. [192]Tong Y NLRP3 inflammasome and its central role in the cardiovascular diseases Oxid. Med. Cell Longev. 2020 2020 4293206 32377298 PMC7180412
  182. [194]Sharma A Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis Diabetes 2021 70 772 787 10.2337/db20-0357 33323396 · DOI
  183. [195]Zeng W The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages Sci. Rep. 2021 11 19305 10.1038/s41598-021-98437-3 34588488 PMC8481539 · DOI
  184. [196]Jiang H Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders J. Exp. Med. 2017 214 3219 3238 10.1084/jem.20171419 29021150 PMC5679172 · DOI
  185. [197]Li Y VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis Exp. Cell Res. 2020 389 111847 10.1016/j.yexcr.2020.111847 31972218 · DOI
  186. [198]C. Stigliano, et al. Methotraxate-loaded hybrid nanoconstructs target vascular lesions and inhibit atherosclerosis progression in ApoE(-/-) mice. Adv Healthc Mater6, (2017). 28402587
  187. [199]Li C Site-specific microRNA-33 antagonism by pH-responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity Adv. Funct. Mater. 2020 30 2002131 10.1002/adfm.202002131 · DOI
  188. [200]Zhong Y “Plug and Play” functionalized erythrocyte nanoplatform for target atherosclerosis management ACS Appl. Mater. Interfaces 2021 13 33862 33873 10.1021/acsami.1c07821 34256560 · DOI
  189. [201]Wang Y Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications Theranostics 2021 11 164 180 10.7150/thno.47841 33391468 PMC7681077 · DOI
  190. [202]Momtazi-Borojeni AA PCSK9 and inflammation: a review of experimental and clinical evidence Eur. Heart J. Cardiovasc. Pharmacother. 2019 5 237 245 10.1093/ehjcvp/pvz022 31236571 · DOI
  191. [203]Seidah NG Awan Z Chretien M Mbikay M PCSK9: a key modulator of cardiovascular health Circ. Res. 2014 114 1022 1036 10.1161/CIRCRESAHA.114.301621 24625727 · DOI
  192. [204]Duan Y Peroxisome proliferator-activated receptor gamma activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression J. Biol. Chem. 2012 287 23667 23677 10.1074/jbc.M112.350181 22593575 PMC3390641 · DOI
  193. [205]Seidah NG Prat A The proprotein convertases are potential targets in the treatment of dyslipidemia J. Mol. Med. 2007 85 685 696 10.1007/s00109-007-0172-7 17351764 · DOI
  194. [206]Tao, R. et al. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J. Biol. Chem.288, 29252–29259 (2013). PMC3795227 23974119
  195. [207]Seidah NG The proprotein convertases, 20 years later Methods Mol. Biol. 2011 768 23 57 10.1007/978-1-61779-204-5_3 21805237 · DOI
  196. [208]Benjannet S NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol J. Biol. Chem. 2004 279 48865 48875 10.1074/jbc.M409699200 15358785 · DOI
  197. [209]Ragusa R PCSK9 and atherosclerosis: looking beyond LDL regulation Eur. J. Clin. Invest. 2021 51 e13459 10.1111/eci.13459 33236356 · DOI
  198. [210]Ding Z Cross-talk between LOX-1 and PCSK9 in vascular tissues Cardiovasc. Res. 2015 107 556 567 10.1093/cvr/cvv178 26092101 · DOI
  199. [211]Giunzioni I Local effects of human PCSK9 on the atherosclerotic lesion J. Pathol. 2016 238 52 62 10.1002/path.4630 26333678 PMC5346023 · DOI
  200. [212]Ding, Z. et al. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc. Res.116, 908–915 (2020). 31746997

200 of 345 shown

Cited by

Sorted by citations

Authors
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M.
Affiliations
Hebei Medical University (CN)
Corresponding author
Han, Mei
ORCID
Han, Mei
Venue
Signal Transduction and Targeted Therapy
Publisher
Springer Science and Business Media LLC
Published
2022-04-22
Volume
7
Issue
1
Pages
131-131
ISSN
2059-3635 (ISSN-L)
DOI
10.1038/s41392-022-00955-7
PMC
PMC9033871
OpenAlex
W4224251997
Cited by
1,183
References
33
Citations by year
2026: 262 · 2025: 456 · 2024: 301 · 2023: 139 · 2022: 25
FWCI
24.21
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (91739301, 91849102, QN2020167, H2019206028, H2021206006)
  • Natural Science Foundation of Hebei Province (H2019206028, H2021206006, 91849102, 91739301)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
atherosclerosis, inflammation, NLRP3 inflammasome, IL-1β, Toll-like receptors, PCSK9, Notch signaling, Wnt signaling, innate and adaptive immunity, atherosclerosis regression, anti-inflammatory therapy, inflammatory signaling
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Humans, Inflammation, Signal Transduction, Atherosclerosis, Genome-Wide Association Study, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review